Investigation on LASSBio-1971 and LASSBio-1974 Cellular Cytotoxic Mechanism and Their Comparative DMPK Profile

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Emerging resistance to EGFR inhibitors in NSCLC, particularly EGFR_L858R/T790M mutations, necessitates novel therapeutic strategies.
• Dual or multi-target molecules offer a promising approach to overcome acquired resistance mechanisms.

Purpose of the Study:

• To evaluate synthetic acrylamide quinoxaline derivatives as potential anti-cancer agents.
• To assess their efficacy against NSCLC cell lines with various EGFR mutations.
• To compare their in vitro pharmacokinetic (DMPK) profiles.

Main Methods:

• Cytotoxicity assays (MTT, Sulforhodamine B) and apoptosis induction.
• EGFR inhibition assays, cell cycle analysis via flow cytometry, and immunofluorescence microscopy.
• In vitro assessment of cell membrane permeability (PAMPA) and metabolic stability in rat liver microsomes.

Main Results:

• LASSBio-1971 demonstrated potent EGFR inhibition and favorable in vitro PK properties, including high gastrointestinal and blood-brain barrier permeability.
• LASSBio-1974 exhibited nonselective inhibition of EGFR and mitotic machinery, inducing apoptosis and cell cycle arrest.
• Both compounds showed equipotent cytotoxic effects on human NSCLC lines but differed in their PK profiles.

Conclusions:

• LASSBio-1971 and LASSBio-1974 are effective EGFR inhibitors against NSCLC cell lines.
• LASSBio-1971 possesses favorable pharmacokinetic properties for further development.
• LASSBio-1974's dual EGFR and antimicrotubule activity requires further investigation.